An Open-Label Extension Study of BPN14770 in Subjects With Fragile X Syndrome

Inclusion criteria

• ✓. Subject has completed the Week 13 visit, whether on treatment or discontinued from treatment, from one of two parent clinical trials with
• ✓. Study 204
• ✓. Study 301 Subjects who discontinued study treatment early due to AEs deemed related to study treatment by the investigator in one of the parent studies will NOT be eligible, regardless of whether the Week 13 visit was completed.
• ✓. Subjects with a history of seizure disorder who are currently receiving treatment with antiepileptics must have remained seizure-free during the parent study. Any subject experiencing a seizure during the parent study is not eligible to continue into this long-term safety study.
• ✓. Subject must be willing to practice barrier methods of contraception while on study, if sexually active. Abstinence is also considered a reasonable form of birth control in this study population.
• ✓. Subject has a parent, legal authorized guardian, or consistent caregiver.
• ✓. Subject and caregiver are able to attend the clinic regularly and reliably.
• ✓. If subject is his own legal guardian, he is able to understand and sign an informed consent form to participate in the study.